Natural Capsules Ltd Stock Price Today (NSE: NATCAPSUQ)
Fundamental Score
Natural Capsules Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Natural Capsules Ltd share price today is ₹151.74, up +0.30% on NSE/BSE as of 17 June 2026. Natural Capsules Ltd (NATCAPSUQ) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹184.79 (Cr). The 52-week high for NATCAPSUQ share price is ₹296.00 and the 52-week low is ₹136.36. The company has a Return on Equity (ROE) of 0.28% and a debt-to-equity ratio of 0.46.
Natural Capsules Ltd Share Price Chart — NSE/BSE Historical Performance
Natural Capsules Ltd share price chart: 5.91% return over the past month. 52-week high ₹296.00, 52-week low ₹136.36.
Natural Capsules Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹161.60 | ₹161.65 | ₹155.40 | ₹158.67 | 1.15K (Cr) | |
| ₹162.81 | ₹163.00 | ₹158.00 | ₹159.93 | 3.05K (Cr) | |
| ₹160.00 | ₹166.90 | ₹160.00 | ₹162.62 | 16.47K (Cr) | |
| ₹156.80 | ₹176.90 | ₹153.00 | ₹167.98 | 26.46K (Cr) | |
| ₹153.00 | ₹155.98 | ₹151.00 | ₹152.42 | 4.67K (Cr) | |
| ₹151.30 | ₹154.99 | ₹151.30 | ₹154.77 | 6.70K (Cr) | |
| ₹150.50 | ₹154.40 | ₹150.50 | ₹151.30 | 1.48K (Cr) | |
| ₹152.50 | ₹162.45 | ₹150.50 | ₹151.72 | 4.58K (Cr) | |
| ₹156.93 | ₹157.80 | ₹152.10 | ₹154.38 | 5.70K (Cr) | |
| ₹156.85 | ₹157.90 | ₹152.02 | ₹156.93 | 1.79K (Cr) |
Natural Capsules Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹162.81 | ₹163.00 | ₹155.40 | ₹158.67 | -2.54% | |
| ₹155.01 | ₹182.80 | ₹150.00 | ₹162.62 | +4.91% | |
| ₹145.41 | ₹181.32 | ₹145.41 | ₹154.46 | +6.22% | |
| ₹144.00 | ₹165.50 | ₹136.36 | ₹144.35 | +0.24% | |
| ₹169.00 | ₹190.00 | ₹149.00 | ₹153.87 | -8.95% | |
| ₹165.99 | ₹200.49 | ₹154.99 | ₹163.96 | -1.22% | |
| ₹183.80 | ₹195.40 | ₹160.00 | ₹166.00 | -9.68% | |
| ₹206.40 | ₹215.66 | ₹173.00 | ₹185.43 | -10.16% | |
| ₹275.00 | ₹282.00 | ₹205.25 | ₹208.50 | -24.18% | |
| ₹196.87 | ₹296.00 | ₹186.63 | ₹274.10 | +39.23% | |
| ₹213.00 | ₹228.09 | ₹193.07 | ₹196.49 | -7.75% | |
| ₹223.02 | ₹230.00 | ₹210.00 | ₹212.50 | -4.72% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Natural Capsules Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Natural Capsules Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NATCAPSUQ across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Strong Operating Margins (15.49%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (22.38% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Balanced Promoter Holding (51.26%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (0.28%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.67%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-1045.90%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-8.30% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-6.33% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-0.47x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-242.01 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Natural Capsules Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Natural Capsules Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Natural Capsules LtdNatural Capsule...Selected✓ NATCAPSUQ • 524654 | 25.3/100 | ₹151.74₹152 | ₹184.79₹184.79 | — — | 0.28%Poor 0.28% Poor | 2.67%Poor 2.67% Poor | 0.46Excellent 0.5 Excellent | -6.33%Poor -6.33% Poor | 22.38%Excellent 22.38% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Natural Capsules Ltd PE Ratio History
Historical price-to-earnings ratio for NATCAPSUQ — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.63 | ₹166.00 | 264.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Natural Capsules Ltd Dividend History
Annual cash dividends paid by NATCAPSUQ — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹0.93 Cr |
| FY 2023 | ₹0.77 Cr |
| FY 2022 | ₹0.62 Cr |
| FY 2021 | ₹0.37 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Natural Capsules Ltd Quarterly Performance
Latest quarterly metrics for NATCAPSUQ — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
11.11%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-1045.90%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
22.38%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-6.33%
Compounded annual net profit growth over 5 years
Natural Capsules Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NATCAPSUQ — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Natural Capsules Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Natural Capsules Ltd (NATCAPSUQ) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Natural Capsules Ltd
About NATCAPSUQ (Natural Capsules Ltd)
Natural Capsules Ltd is a pioneering force in the pharmaceutical manufacturing landscape, specializing in the development and global distribution of advanced capsule solutions. Wit...h a firm commitment to quality and innovation, the company produces a diverse portfolio of hard gelatin and cellulose capsule shells, catering to the evolving needs of the pharmaceutical and nutraceutical industries. Their state-of-the-art manufacturing facilities adhere to the highest international standards, ensuring consistent product excellence and safety. The company is strategically positioned to serve both domestic and international markets, leveraging its expertise and advanced technologies to deliver superior capsule solutions to a global clientele. Focusing on specialized requirements, Natural Capsules Ltd offers a range of tailored capsule shells, each engineered to meet specific formulation and delivery demands. This includes bovine spongiform encephalopathy (BSE) and transmissible spongiform encephalopathy (TSE) free gelatin, appealing to stringent safety standards, as well as shiny gelatin and sodium lauryl sulfate-free gelatin alternatives. They also provide halal-certified gelatin, fast-release gelatin options, and customized printed gelatin/cellulose capsules for branding purposes. In addition, the company offers vegetarian and enteric capsule shells, catering to a diverse range of consumer preferences and therapeutic applications, demonstrating their dedication to delivering comprehensive solutions. Beyond capsule manufacturing, Natural Capsules Ltd has expanded its capabilities to include the formulation of pharmaceutical dosage forms specifically within capsule dosage form. This strategic integration allows them to offer comprehensive solutions, from capsule shell design to final drug product manufacturing. By combining its expertise in capsule technology with advanced formulation capabilities, the company provides its clients with end-to-end services, streamlining the drug development process and ensuring product quality. Their dedication to innovation and customer satisfaction positions them as a trusted partner for pharmaceutical companies seeking cutting-edge capsule solutions and reliable manufacturing services.
Company Details
Key Leadership
NATCAPSUQ Share Price: Frequently Asked Questions
What is the current share price of Natural Capsules Ltd?
Natural Capsules Ltd (NATCAPSUQ) trades at ₹151.74 on NSE and BSE. Market cap ₹184.79 (Cr). Educational data only.
What is the P/E ratio of Natural Capsules Ltd?
Natural Capsules Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Natural Capsules Ltd?
Natural Capsules Ltd has a Bull Run score of 25.3/100 based on 25+ financial parameters.
Does Natural Capsules Ltd pay dividends?
Natural Capsules Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Natural Capsules Ltd?
Natural Capsules Ltd has ROE of 0.28%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Natural Capsules Ltd?
Natural Capsules Ltd has debt-to-equity of 0.46.
Is Natural Capsules Ltd a good investment?
Bull Run gives Natural Capsules Ltd a score of 25.3/100. This is not investment advice — consult a SEBI-registered advisor.